239 related articles for article (PubMed ID: 35572513)
21. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
Zhang L; Shen X; Yu W; Li J; Zhang J; Zhang R; Li J; Chen L
Ann Med; 2021 Dec; 53(1):1547-1559. PubMed ID: 34459681
[TBL] [Abstract][Full Text] [Related]
22. Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.
Zu C; Wang K; Zhang Q; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):160-166. PubMed ID: 36161295
[TBL] [Abstract][Full Text] [Related]
23. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
[TBL] [Abstract][Full Text] [Related]
24. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
[TBL] [Abstract][Full Text] [Related]
25. [The characteristics and impact on prognosis of cytopenia after anti-BCMA-CAR-T therapy in patients with relapsed and refractory multiple myeloma].
Shen XX; Yao Y; Xia Y; Jin YY; Zhang R; Li JY; Chen LJ
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):507-513. PubMed ID: 38317362
[No Abstract] [Full Text] [Related]
26. Risk factors of acute kidney injury during BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.
Lyu Y; Zhang M; Wei G; Ding S; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):137-143. PubMed ID: 36161296
[TBL] [Abstract][Full Text] [Related]
27. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
Zhao WH; Liu J; Wang BY; Chen YX; Cao XM; Yang Y; Zhang YL; Wang FX; Zhang PY; Lei B; Gu LF; Wang JL; Yang N; Zhang R; Zhang H; Shen Y; Bai J; Xu Y; Wang XG; Zhang RL; Wei LL; Li ZF; Li ZZ; Geng Y; He Q; Zhuang QC; Fan XH; He AL; Zhang WG
J Hematol Oncol; 2018 Dec; 11(1):141. PubMed ID: 30572922
[TBL] [Abstract][Full Text] [Related]
28. [Analysis of Related Early Warning Indexes of Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Treatment].
Ye CY; Zhao LN; Wang SY; Cheng H; Chen W; Qi KM; Wu QY; Li ZY; Xu KL; Cao J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1203-1208. PubMed ID: 34362503
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
30. Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma.
Zhou D; Wang Y; Cheng H; Zhu L; Chen W; Li H; Zhang X; Xia J; Qi Y; Ma S; Zhu F; Yan Z; Qi K; Sang W; Sun H; Li D; Cao J; Li Z; Xu K
J Infect Chemother; 2023 Feb; 29(2):179-185. PubMed ID: 36368473
[TBL] [Abstract][Full Text] [Related]
31. Effect of anti-CD19 chimeric antigen receptor T cell therapy in children with relapsed or refractory acute B-lymphocytic leukemia and its prognosis.
Li N; Li H
J BUON; 2021; 26(1):159-165. PubMed ID: 33721447
[TBL] [Abstract][Full Text] [Related]
32. [Observation of liver indexes in patients with relapsed/refractory multiple myeloma treated with CAR-T-cells based on BCMA].
Sun Q; Qi YK; Qi KM; Yan ZL; Cheng H; Chen W; Zhu F; Sang W; Li DP; Cao J; Shi M; Li ZY; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):832-837. PubMed ID: 38049335
[No Abstract] [Full Text] [Related]
33. Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis.
Soltantabar P; Sharma S; Wang D; Lon HK; Czibere A; Hickmann A; Elmeliegy M
Clin Pharmacol Ther; 2024 Jun; 115(6):1258-1268. PubMed ID: 38459622
[TBL] [Abstract][Full Text] [Related]
34. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
[TBL] [Abstract][Full Text] [Related]
35. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study.
Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D
Transplant Cell Ther; 2024 Jun; 30(6):630.e1-630.e8. PubMed ID: 38458477
[TBL] [Abstract][Full Text] [Related]
36. A comprehensive analysis of coagulopathy during anti-B cell maturation antigen chimeric antigen receptor-T therapy in multiple myeloma, a retrospective study based on LEGEND-2.
Liu R; Lv Y; Hong F; Zhao W; Lei B; Liu J; Zhang W; He A; Wang F
Hematol Oncol; 2023 Oct; 41(4):704-717. PubMed ID: 37186314
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
Wang Y; Cao J; Gu W; Shi M; Lan J; Yan Z; Jin L; Xia J; Ma S; Liu Y; Li H; Pan B; Chen W; Fei X; Wang C; Xie X; Yu L; Wang G; Li H; Jing G; Cheng H; Zhu F; Sun H; Sang W; Li D; Li Z; Zheng J; Xu K
J Clin Oncol; 2022 Jul; 40(20):2246-2256. PubMed ID: 35333600
[TBL] [Abstract][Full Text] [Related]
38. Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma.
Josyula S; Pont MJ; Dasgupta S; Song X; Thomas S; Pepper G; Keane-Candib J; Stevens-Ayers TL; Ochs HD; Boeckh MJ; Riddell SR; Cowan AJ; Krantz EM; Green DJ; Hill JA
Transplant Cell Ther; 2022 Jun; 28(6):304.e1-304.e9. PubMed ID: 35288345
[TBL] [Abstract][Full Text] [Related]
39. [Toxicity Management and Efficacy Evaluation of BCMA-CART in the Treatment of Relapsed and Refractory Multiple Myeloma].
Zhang XY; Ding HY; Gang DX; He XY; Ma YY; Qian HL; Lin XR; Xing CY; Zhang Y; Jiang SF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):466-475. PubMed ID: 35395981
[TBL] [Abstract][Full Text] [Related]
40. Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies.
Xu QW; Xu H; Xue L; Wang L; Zhang XH; Song KD; Yao W; Wan X; Tong J; Liu HL; Liu X; Zhu XY; Sun ZM; Wang XB
Transfus Apher Sci; 2022 Dec; 61(6):103473. PubMed ID: 35672235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]